Hirano T, Mamo J C, Nagano S, Sugisaki T
Department of Internal Medicine, Itabashi Central General Hospital, Tokyo, Japan.
Nephron. 1991;58(1):95-100. doi: 10.1159/000186385.
Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats. Rats made nephrotic exhibited severe hyperlipidemia with increases in all major lipoprotein fractions. Probucol treatment of nephrotic rats significantly lowered plasma triglyceride (TG), cholesterol (Ch) phospholipid (PL) and apoprotein B associated with very-low-density and low-density lipoprotein and Ch and PL in high-density lipoprotein (HDL). Malondialdehyde (MDA) associated with the lipoproteins was significantly elevated in nephrotic rats and probucol treatment also lowered MDA concentration in all major lipoproteins. In control rats probucol moderately, but significantly, reduced plasma TG and HDL-Ch concentrations. Proteinuria associated with nephrosis was decreased significantly by treatment with probucol. Probucol treatment did not affect blood urea nitrogen and plasma creatinine levels. A significant positive correlation existed between the amount of protein excreted in urine and the plasma lipid concentrations in all nephrotic rats, suggesting that the hypolipidemic effect of probucol may attenuate proteinuria associated with nephrosis. These results suggest that probucol may be a favorable treatment for hyperlipidemia associated with nephrotic syndrome.
用普罗布考治疗与肾病综合征相关的高脂血症，并在嘌呤霉素氨基核苷诱导的肾病大鼠中检测血浆脂蛋白脂质浓度和尿蛋白排泄的变化。制成肾病模型的大鼠表现出严重的高脂血症，所有主要脂蛋白组分均增加。用普罗布考治疗肾病大鼠可显著降低血浆甘油三酯（TG）、胆固醇（Ch）、磷脂（PL）以及与极低密度脂蛋白和低密度脂蛋白相关的载脂蛋白B，以及高密度脂蛋白（HDL）中的Ch和PL。肾病大鼠中与脂蛋白相关的丙二醛（MDA）显著升高，普罗布考治疗也降低了所有主要脂蛋白中的MDA浓度。在对照大鼠中，普罗布考适度但显著地降低了血浆TG和HDL-Ch浓度。用普罗布考治疗可显著降低与肾病相关的蛋白尿。普罗布考治疗不影响血尿素氮和血浆肌酐水平。所有肾病大鼠尿中排泄的蛋白量与血浆脂质浓度之间存在显著正相关，提示普罗布考的降血脂作用可能减轻与肾病相关的蛋白尿。这些结果表明，普罗布考可能是治疗与肾病综合征相关的高脂血症的一种有效药物。
